Management of superficial venous thrombosis in unevaluated situations: Cancer,severe renal impairment,pregnancy and post-partum

Abstract

Background

Information is lacking as to the management of patients with superficial venous thrombosis (SVT) whose profile has been excluded from trials, such as patients with active cancer, severe renal impairment, or pregnancy.

Objectives

To describe the frequency and management of SVT occurring in these situations.

Methods

We retrospectively analyzed the frequency, management and evolution of all patients with isolated SVT associated with either active cancer, severe renal impairment, or pregnant or postpartum women, diagnosed in 2 university hospital between January 1st, 2015 and December 31st, 2016.

Results

Of the 594 isolated SVTs individualized from the 7941 reports screened, 149 SVTs (105 in the upper extremity, 44 in the lower extremity) were analyzed: 94 (63%) associated with active cancer, 27 (18%) with severe renal impairment and 30 (20%) pregnant or postpartum women. SVT was treated with anticoagulant in 34 (36%) patients with cancer, 3 (11%) patients with severe renal impairment and 19 (63%) pregnant or postpartum women. At 3-month, 16 patients (10.8%) had a further venous thromboembolic event, 8 (5.4%) major bleeding, and 9 (6.1%) died.

Conclusion

SVT in patients with active cancer, severe renal impairment and pregnant or postpartum women represents a quarter of isolated SVTs diagnosed. Heterogeneity of treatment patterns mainly affects patients with cancer and severe renal impairment. Poor outcomes, although probably linked to morbidity, call for dedicated research in these specific situations.

Keywords

Physician practice patterns superficial vein thrombosis venous thromboembolism cancer renal impairement pregnancy

Get full access to this article

View all access options for this article.

References

Decousus

Quéré

Presles

, POST (Prospective Observational Superficial Thrombophlebitis) Study Groupet al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 2010; 152: 218–224.

Galanaud

J-P

Genty

Sevestre

M-A

, OPTIMEV SFMV investigatorset al. Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. The OPTIMEV study. Thromb Haemost 2011; 105: 31–39.

Decousus

Prandoni

Mismetti

, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010; 363: 1222–1232.

Beyer-Westendorf

Schellong

Gerlach

, SURPRISE Investigatorset al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 2017; 4: e105–e113.

Frappé

Bertoletti

Le Hello

, et al. Evaluation of direct oral anticoagulants in superficial-vein thrombosis. Lancet Haematol 2017; 4: e254. https://doi.org/10.1016/S2352-3026(17)30062-5

Ageno

Dentali

Direct oral anticoagulants for superficial-vein thrombosis. Lancet Haematol 2017; 4: e95–e96.

Décousus

Bertoletti

Frappé

Spontaneous acute superficial vein thrombosis of the legs: do we really need to treat?

J Thromb Haemost 2015; 13: S230–S237.

Di Nisio

Wichers

Middeldorp

Treatment of lower extremity superficial thrombophlebitis. JAMA 2018; 320: 2367–2362.

Kearon

Akl

Comerota

, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e419S–e496S.

10.

Evans

Ratchford

EV.

Catheter-related venous thrombosis. Vasc Med 2018; 23: 411–413.

11.

Schulman

Kearon

, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–694.

12.

Khorana

Francis

CW.

Risk prediction of cancer-associated thrombosis: appraising the first decade and developing the future. Thromb Res 2018; 164: S70–S76.

13.

Decousus

Bourmaud

Fournel

, ONCOCIP Investigatorset al. Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP). Blood 2018; 132: 707–716.

14.

Chopra

Anand

Hickner

, et al. Risk of venous thromboembolism associated with peripherally inserted Central catheters: a systematic review and Meta-analysis. Lancet 2013; 382: 311–325. https://doi.org/10.1016/S0140-6736(13)60592-9

15.

Konstantinides

Torbicki

Agnelli

, Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–3073.

16.

Farge

Bounameaux

Brenner

, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016; 17: e452–e466. https://doi.org/10.1016/S1470-2045(16)30369-2

17.

Bates

Greer

Middeldorp

, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Chest 2012; 141: e691S–e736S.

18.

Catella

Bertoletti

Mismetti

, for the investigators of the RIETE registryet al. Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism. J Thromb Haemost 2020; 18: 1728–1737.

19.

Galanaud

J-P

Blaise

Sevestre

M-A

, et al. Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer. Thromb Res 2018; 171: 179–186.